
From the U.S. Code Online via GPO Access
[wais.access.gpo.gov]
[Laws in effect as of January 23, 2000]
[Document not affected by Public Laws enacted between
  January 23, 2000 and December 4, 2001]
[CITE: 42USC300cc-41]

 
                 TITLE 42--THE PUBLIC HEALTH AND WELFARE
 
                    CHAPTER 6A--PUBLIC HEALTH SERVICE
 
  SUBCHAPTER XXI--RESEARCH WITH RESPECT TO ACQUIRED IMMUNE DEFICIENCY 
                                SYNDROME
 
                     Part D--Office of AIDS Research
 
            subpart i--interagency coordination of activities
 
Sec. 300cc-41. Additional authorities


(a) In general

    In carrying out AIDS research, the Director of the Office--
        (1) shall develop and expand clinical trials of treatments and 
    therapies for infection with the etiologic agent for acquired immune 
    deficiency syndrome, including such clinical trials for women, 
    infants, children, hemophiliacs, and minorities;
        (2) may establish or support the large-scale development and 
    preclinical screening, production, or distribution of specialized 
    biological materials and other therapeutic substances for AIDS 
    research and set standards of safety and care for persons using such 
    materials;
        (3) may support--
            (A) AIDS research conducted outside the United States by 
        qualified foreign professionals if such research can reasonably 
        be expected to benefit the people of the United States;
            (B) collaborative research involving American and foreign 
        participants; and
            (C) the training of American scientists abroad and foreign 
        scientists in the United States;

        (4) may encourage and coordinate AIDS research conducted by any 
    industrial concern that evidences a particular capability for the 
    conduct of such research;
        (5)(A) may acquire, improve, repair, operate, and maintain 
    laboratories, other research facilities, equipment, and such other 
    real or personal property as the Director of the Office determines 
    necessary;
        (B) may make grants for the construction or renovation of 
    facilities; and
        (C) may acquire, without regard to section 34 of title 40 by 
    lease or otherwise through the Administrator of General Services, 
    buildings or parts of buildings in the District of Columbia or 
    communities located adjacent to the District of Columbia for the use 
    of the National Institutes of Health for a period not to exceed ten 
    years; and
        (6) subject to section 284(b)(2) of this title and without 
    regard to section 3324 of title 31 and section 5 of title 41, may 
    enter into such contracts and cooperative agreements with any public 
    agency, or with any person, firm, association, corporation, or 
    educational institution, as may be necessary to expedite and 
    coordinate research relating to acquired immune deficiency syndrome.

(b) Report to Secretary

    The Director of the Office shall each fiscal year prepare and submit 
to the Secretary, for inclusion in the comprehensive report required in 
section 300cc(a) of this title, a report--
        (1) describing and evaluating the progress made in such fiscal 
    year in research, treatment, and training with respect to acquired 
    immune deficiency syndrome conducted or supported by the Institutes;
        (2) summarizing and analyzing expenditures made in such fiscal 
    year for activities with respect to acquired immune deficiency 
    syndrome conducted or supported by the National Institutes of 
    Health; and
        (3) containing such recommendations as the Director considers 
    appropriate.

(c) Projects for cooperation among public and private health entities

    In carrying out subsection (a) of this section, the Director of the 
Office shall establish projects to promote cooperation among Federal 
agencies, State, local, and regional public health agencies, and private 
entities, in research concerning the diagnosis, prevention, and 
treatment of acquired immune deficiency syndrome.

(July 1, 1944, ch. 373, title XXIII, Sec. 2354, formerly Sec. 2351, as 
added Pub. L. 100-607, title II, Sec. 201(4), Nov. 4, 1988, 102 Stat. 
3076; renumbered Sec. 2354 and amended Pub. L. 103-43, title XVIII, 
Sec. 1801(a)(2), (b), June 10, 1993, 107 Stat. 192, 196.)


                               Amendments

    1993--Pub. L. 103-43, Sec. 1801(b)(1), substituted ``Additional'' 
for ``Establishment of'' in section catchline.
    Subsec. (a). Pub. L. 103-43, Sec. 1801(b)(2)(A), in introductory 
provisions substituted ``AIDS research, the Director of the Office'' for 
``research with respect to acquired immune deficiency syndrome, the 
Secretary, acting through the Director of the National Institutes of 
Health''.
    Subsec. (a)(1). Pub. L. 103-43, Sec. 1801(b)(2)(B), redesignated 
par. (3) as (1) and struck out former par. (1) which read as follows:
    ``(A) shall establish an office to be known as the Office of AIDS 
Research, which Office shall be headed by a Director appointed by the 
Director of the National Institutes of Health; and
    ``(B) shall provide administrative support and support services to 
the Director of such Office;''.
    Subsec. (a)(2). Pub. L. 103-43, Sec. 1801(b)(2)(B), (E), 
redesignated par. (4) as (2), substituted ``AIDS research'' for 
``research relating to acquired immune deficiency syndrome'', and struck 
out former par. (2) which read as follows: ``shall coordinate activities 
relating to acquired immune deficiency syndrome conducted by the 
national research institutes and the agencies of the National Institutes 
of Health;''.
    Subsec. (a)(3). Pub. L. 103-43, Sec. 1801(b)(2)(B), (C), (E), 
redesignated par. (5) as (3), struck out ``, in consultation with the 
advisory council for the appropriate national research institute of the 
National Institutes of Health,'' after ``may'' in introductory 
provisions, and substituted ``AIDS research'' for ``research relating to 
acquired immune deficiency syndrome'' in subpar. (A). Former par. (3) 
redesignated (1).
    Subsec. (a)(4). Pub. L. 103-43, Sec. 1801(b)(2)(B), (E), 
redesignated par. (6) as (4) and substituted ``AIDS research'' for 
``research relating to acquired immune deficiency syndrome''. Former 
par. (4) redesignated (2).
    Subsec. (a)(5). Pub. L. 103-43, Sec. 1801(b)(2)(B), (D), 
redesignated par. (7) as (5), in subpar. (A) struck out ``, in 
consultation with such advisory council,'' after ``may'' and substituted 
``Director of the Office determines'' for ``Director of the National 
Institutes of Health determines'', and in subpars. (B) and (C) struck 
out ``, in consultation with such advisory council,'' after ``may''. 
Former par. (5) redesignated (3).
    Subsec. (a)(6) to (8). Pub. L. 103-43, Sec. 1801(b)(2)(B), 
redesignated pars. (6) to (8) as (4) to (6), respectively.
    Subsec. (b). Pub. L. 103-43, Sec. 1801(b)(3), substituted ``The 
Director of the Office shall'' for ``The Director of the National 
Institutes of Health, acting through the Director of the Office of AIDS 
Research, shall''.
    Subsec. (c). Pub. L. 103-43, Sec. 1801(b)(4), substituted ``the 
Director of the Office shall'' for ``the Director of the National 
Institutes of Health shall''.
